- Home
- PHGE vs SPPL Comparison
PHGE vs SPPL Comparison
Compare PHGE & SPPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- SPPL
- Stock Information
- Founded
- PHGE 2015
- SPPL 2016
- Country
- PHGE Israel
- SPPL Singapore
- Employees
- PHGE N/A
- SPPL N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- SPPL
- Sector
- PHGE Health Care
- SPPL
- Exchange
- PHGE Nasdaq
- SPPL Nasdaq
- Market Cap
- PHGE 11.0M
- SPPL 10.4M
- IPO Year
- PHGE N/A
- SPPL 2023
- Fundamental
- Price
- PHGE $0.49
- SPPL $2.74
- Analyst Decision
- PHGE Strong Buy
- SPPL
- Analyst Count
- PHGE 1
- SPPL 0
- Target Price
- PHGE $15.00
- SPPL N/A
- AVG Volume (30 Days)
- PHGE 278.8K
- SPPL 17.1K
- Earning Date
- PHGE 08-13-2025
- SPPL 01-01-0001
- Dividend Yield
- PHGE N/A
- SPPL N/A
- EPS Growth
- PHGE N/A
- SPPL N/A
- EPS
- PHGE N/A
- SPPL N/A
- Revenue
- PHGE N/A
- SPPL $2,764,846.00
- Revenue This Year
- PHGE N/A
- SPPL N/A
- Revenue Next Year
- PHGE N/A
- SPPL N/A
- P/E Ratio
- PHGE N/A
- SPPL N/A
- Revenue Growth
- PHGE N/A
- SPPL N/A
- 52 Week Low
- PHGE $0.34
- SPPL $2.02
- 52 Week High
- PHGE $3.86
- SPPL $16.80
- Technical
- Relative Strength Index (RSI)
- PHGE 51.35
- SPPL 37.93
- Support Level
- PHGE $0.34
- SPPL $2.56
- Resistance Level
- PHGE $0.51
- SPPL $2.83
- Average True Range (ATR)
- PHGE 0.05
- SPPL 0.18
- MACD
- PHGE 0.01
- SPPL -0.01
- Stochastic Oscillator
- PHGE 77.53
- SPPL 11.31
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About SPPL SIMPPLE LTD.
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.